Correlation of Serum Biomarker DT with Clinical Outcome
| Endpoint | 5-y survival (%) | 95% CI interval | P |
| PFS according to baseline biomarker DT | 0.0003 | ||
| ≥9 mo | 41.8 | 21.3–61.1 | |
| <9 mo | 0 | — | |
| PFS according to DT impact after pRAIT | 0.023 | ||
| ≥100% increase | 37.9 | 17.0–58.8 | |
| <100% increase | 12.5 | 2.1–32.8 | |
| OS according to baseline biomarker DT | 0.025 | ||
| ≥9 mo | 61.1 | 25.8–83.6 | |
| <9 mo | 20.9 | 4.1–46.5 | |
| OS according to DT impact after pRAIT | 0.034 | ||
| ≥100% increase | 68.2 | 38.1–85.9 | |
| <100% increase | 18.3 | 1.3–51.4 |